跳至主要内容
临床试验/ISRCTN82062639
ISRCTN82062639已完成4 期

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A randomised double-blind placebo-controlled trial (SEESAW)

niversity of Leicester0 个研究点目标入组 68 人开始时间: 2016年7月20日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
68

研究概览

简要总结

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35441435/ (added 26/10/2022)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Male and postmenopausal female participants aged between 30-70 years of age inclusive
  • 2. Type 2 diabetes on diet and lifestyle control or stable dose of metformin only for at least 3 months
  • 3. Stable weight (less than 5% change in body weight in last 3 months) – determined by self-reporting or documentation in clinical records
  • 4. HbA1c 48-86mmol/mol (6.5 - 10%)
  • 5. eGFR=60ml/min/1.73m2
  • 6. BMI = 25kg/m2
  • 7. Able and willing to give informed consent
  • 8. Able to understand English

排除标准

  • 1. Females who are not postmenopausal (as menstrual cycle can affect appetite hormone concentrations) which is defined as 2 years post last menstrual period <50 years of age or 1 year post last menstrual period >50 years of age.”
  • 2. Type 2 diabetes on any other glucose lowering treatment except metformin
  • 3. Patients with Type 1 diabetes
  • 4. Patients on loop diuretics
  • 5. Age <30 years and >70 years
  • 6. BMI <25kg/m2
  • 7. Not able to give informed consent
  • 8. Not able to understand English
  • 9. Moderate to severe renal impairment (eGFR<60ml/min/1.73m2)
  • 10. Unstable diabetes i.e. HbA1c >86mmol/mol (10%), recent hospital admission with diabetic emergency in last 3 months
  • 11. Patients with familial renal glycosuria
  • 12. Patients with recurrent balanitis, vaginal or urinary tract infections
  • 13. Shift workers
  • 14. Patients who have participated in another study of an investigational medicinal product in the last 3 months
  • 15. Active malignancy
  • 16. Serious illness with a life-expectancy of less than 1 year
  • 17. Hypersensitivity to Empagliflozin (Jardiance™) or to any of the excipients
  • 18. Patients with latent autoimmune diabetes in adults (LADA)
  • 19. Patients with a history of chronic pancreatitis
  • 20. Evidence of conditions that lead to restricted food intake or severe dehydration
  • 21. Patients with a history of excessive alcohol consumption
  • 22. Patients on a severely calorie restricted diet (i.e., =800 calories per day)

研究者

发起方
niversity of Leicester

相似试验